title: Current status of malaria vaccine development.
abstract: There is an urgent need to develop an effective vaccine against malaria--a disease that has approximately 10% of the world population at risk of infection at any given time. The economic burden this disease puts on the medico-social set-up of countries in Sub-Saharan Africa and South East Asia is phenomenal. Increasing drug resistance and failure of vector control strategies have necessitated the search for a suitable vaccine that could be integrated into the extended program of immunization for countries in the endemic regions. Malaria vaccine development has seen a surge of activity in the last decade or so owing largely to the advances made in the fields of genetic engineering and biotechnology. This revolution has brought sweeping changes in the understanding of the biology of the parasite and has helped formulate newer more effective strategies to combat the disease. Latest developments in the field of malaria vaccine development will be discussed in this chapter.
authors.affiliation: Malaria Research Group, International Center for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110067, India. Virander@icgeb.res.in
authors.forename: Virander Singh
authors.initials: VS
authors.lastname: Chauhan
authors.forename: Devesh
authors.initials: D
authors.lastname: Bhardwaj
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D000962:Antimalarials / Q000008:administration & dosage / Q000276:immunology; D016503:Drug Delivery Systems / Q000379:methods; D056890:Eukaryota / Q000145:classification / Q000187:drug effects* / Q000276:immunology*; D006801:Humans; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000008:administration & dosage* / Q000138:chemical synthesis*; D014614:Vaccines, Synthetic / Q000494:pharmacology
chemical_list: D000953:Antigens, Protozoan; D000962:Antimalarials; D017780:Malaria Vaccines; D014614:Vaccines, Synthetic